Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Novartis AG

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

Financing Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

Commercial Deals

Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round

The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.

Reimbursement Pricing Debate

Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Companies Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Admune Therapeutics
    • Amblyotech, Inc.
    • Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
    • Aspen Japan K.K.
    • Biocine
    • CELLforCURE SASU
    • Chiron Corporation
    • CIBA-GEIGY
    • Corthera Inc.
    • CoStim Pharmaceuticals Inc.
    • ESBATech AG
    • Fougera Pharmaceuticals, Inc.
    • Gyroscope Therapeutics Limited
    • Hexal AG
    • Lek Pharmaceuticals, Inc.
    • Matrix Pharmaceuticals
    • NeuTec Pharma
    • Novartis Groupe France S.A.
    • Novartis Pharmaceuticals
    • Novartis Oncology
    • Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
    • PowerVision, Inc.
    • Protez Pharmaceuticals
    • Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
    • Ebewe Pharma)
    • Selexys Pharmaceuticals Corporation
    • Speedel Holding
    • Spinifex Pharmaceuticals Pty. Ltd.
    • Transcend Medical, Inc.
    • Encore Vision, Inc.
    • Ziarco Group Limited
    • AveXis, Inc.
    • BioLife Cell Bank, Inc.
    • Endocyte, Inc.
    • IFM Tre
    • Zyma SA
    • Annovation Biopharma, Inc.
    • Boxford Subsidiary
    • Curacyte Discovery GmbH
    • Incline Therapeutics, Inc.
    • ProFibrix B.V.
    • Rempex Pharmaceuticals, Inc.
    • Targanta Therapeutics Corporation
    • Tenaxis Medical
    • The Medicines Company
    • Novartis Gene Therapies
UsernamePublicRestriction

Register